Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation?
51m
·
StockMarketFunding
·
http://www.StockMarketFunding.com Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? Wall St is hyping the suicidal results. We believe today's "pre market" manipulation in price action caused some large institutions to take a short position going into the move and the FDA Program Schedule Released at 8 AM today did not show any meaningful new data. Premarket high was $29.50 and now we're trading at $24.50 $5 dollars lower. The new breakthrough in Human Genome Sciences Benlysta drug approval for lupus patients. SMF will cover the pros and the cons of the HGSI new drug and benefits to humanity. We will take a look at one of the most positive developments in "biotechnology" in the past 50 years. We have highlighted HGSI and the longer term trends relative to the current drug developments. BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS, which was discovered by HGS in 1996. We and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and commercialization agreement entered into in 2006. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body’s own healthy tissues.
BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). In June 2010, HGS and GSK submitted regulatory applications seeking approval to market BENLYSTA in the United States and Europe. The FDA has granted BENLYSTA a priority review designation with a Prescription Drug User Fee Act (PDUFA) target date of December 9, 2010 – so it is possible that BENLYSTA could receive regulatory approval in the United States before the end of 2010.
The episode Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? from the podcast StockMarketFunding has a duration of
51:37. It was first published
More episodes from StockMarketFunding
2012 Global Economic Recession & Banking Crisis
Stocks Surge 3% After Central Bank Action; Dow Up More Than 400. In this live talk radio show we'll cover the 2012 Global Economic Recession possibilities, the recent Banking Crisis, if it's time to invest in gold, and what's next for Apple Computers (AAPL). Financial Banking Crisis 2011 S&P Downgrade Spree, Hits 37 U.S. Banks! In this live stock market education radio show will cover all the recent banking sector moves after hours as markets have just been dealt a dose of global bank downgrades by S&P. Global stress on the financial markets means forced liquidation, margin debt selling this is the main reason why we saw NASDAQ and technology related stock selloff the hardest today. Will Germany save Europe? S&P Downgrades Goldman Sachs, Bank Of America, Wells Fargo, and Citigroup to an "A-" minus rating, down from an "A" rating. Bank of America N.A. (BAC) to A from A+Bank of New York Mellon Corp. (BK) to A+ from AA-Barclays PLC (BCS) to A from A+Citibank N.A. (C) to A from A+Goldman Sachs & Co. (GS) to A from A+JPMorgan Chase & Co. (JPM) to A from A+Morgan Stanley (MS) to A- from AWells Fargo Bank N.A. (WFC) to AA- from AA
Stock Market Index Analysis and Market Commentary & Market Experiences
http://www.stockmarketfunding.com Stock Market Index Analysis and Market Commentary & Market Experiences Q&A. Live stock market trading analysis for traders and investors looking to understand the overbought and oversold conditions of the stock market.
Stock Market Index Analysis and Market Commentary
http://www.stockmarketfunding.com Stock Market Index Analysis and Market Commentary Q&A. Live stock market trading analysis for traders and investors looking to understand the overbought and oversold conditions of the stock market.
Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation?
http://www.StockMarketFunding.com Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? Wall St is hyping the suicidal results. We believe today's "pre market" manipulation in price action caused some large institutions to take a short position going into the move and the FDA Program Schedule Released at 8 AM today did not show any meaningful new data. Premarket high was $29.50 and now we're trading at $24.50 $5 dollars lower. The new breakthrough in Human Genome Sciences Benlysta drug approval for lupus patients. SMF will cover the pros and the cons of the HGSI new drug and benefits to humanity. We will take a look at one of the most positive developments in "biotechnology" in the past 50 years. We have highlighted HGSI and the longer term trends relative to the current drug developments. BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS, which was discovered by HGS in 1996. We and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and commercialization agreement entered into in 2006. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body’s own healthy tissues.
BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). In June 2010, HGS and GSK submitted regulatory applications seeking approval to market BENLYSTA in the United States and Europe. The FDA has granted BENLYSTA a priority review designation with a Prescription Drug User Fee Act (PDUFA) target date of December 9, 2010 – so it is possible that BENLYSTA could receive regulatory approval in the United States before the end of 2010.
Human Genome Sciences Benlysta Drug Approval for Lupus Patients
New Break through in Human Genome Sciences Benlysta drug approval for lupus patients. SMF will cover the pros and the cons of the HGSI new drug and benefits to humanity. We will take a look at one of the most positive developments in "biotechnology" in the past 50 years. We have highlighted HGSI and the longer term trends relative to the current drug developments. BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS, which was discovered by HGS in 1996. We and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and commercialization agreement entered into in 2006. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body’s own healthy tissues.
BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). In June 2010, HGS and GSK submitted regulatory applications seeking approval to market BENLYSTA in the United States and Europe. The FDA has granted BENLYSTA a priority review designation with a Prescription Drug User Fee Act (PDUFA) target date of December 9, 2010 – so it is possible that BENLYSTA could receive regulatory approval in the United States before the end of 2010.